Mbracetrx
1 known investors
MBrace Therapeutics develops first-in-class antibody-drug conjugate (ADC) cancer therapeutics using its proprietary in vivo SPARTA target discovery technology to identify novel targets on cancer cells. Its lead ADC products are in clinical trials for cancers with unmet treatment needs.
BiotechHealthtech
Investors · 1
Frequently asked questions
- What does Mbracetrx do?
- MBrace Therapeutics develops first-in-class antibody-drug conjugate (ADC) cancer therapeutics using its proprietary in vivo SPARTA target discovery technology to identify novel targets on cancer cells. Its lead ADC products are in clinical trials for cancers with unmet treatment needs.
- Who are Mbracetrx's investors?
- Mbracetrx's investors include Alta Partners.